The stock of Editas Medicine, Inc. (NASDAQ:EDIT) is a huge mover today! The stock increased 0.46% or $0.14 during the last trading session, reaching $30.46. About 636,728 shares traded. Editas Medicine, Inc. (NASDAQ:EDIT) has risen 4.14% since December 10, 2018 and is uptrending. It has outperformed by 4.14% the S&P500.
The move comes after 5 months positive chart setup for the $1.56 billion company. It was reported on Dec, 10 by Barchart.com. We have $33.20 PT which if reached, will make NASDAQ:EDIT worth $140.67M more.
Analysts await Editas Medicine, Inc. (NASDAQ:EDIT) to report earnings on February, 27. They expect $0.04 EPS, up 107.69 % or $0.56 from last year’s $-0.52 per share. EDIT’s profit will be $2.05M for 190.38 P/E if the $0.04 EPS becomes a reality. After $-0.66 actual EPS reported by Editas Medicine, Inc. for the previous quarter, Wall Street now forecasts -106.06 % EPS growth.
More notable recent Editas Medicine, Inc. (NASDAQ:EDIT) news were published by: Nasdaq.com which released: “Don’t Judge a Month by its First Day – Nasdaq” on December 03, 2019, also Nasdaq.com with their article: “CAC 40 Slides On Trade Concerns – Nasdaq” published on December 09, 2019, Nasdaq.com published: “No CRISPR Required: This Forgotten Gene Editing Stock Is Up 50% in 5 Weeks – Nasdaq” on December 09, 2019. More interesting news about Editas Medicine, Inc. (NASDAQ:EDIT) were released by: Fool.com and their article: “Here’s Why Editas Medicine Jumped 45.3% in November – The Motley Fool” published on December 04, 2019 as well as Nasdaq.com‘s news article titled: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – Nasdaq” with publication date: November 26, 2019.
Editas Medicine, Inc. operates as a genome editing company. The company has market cap of $1.56 billion. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It currently has negative earnings. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.